About Us
CytoImage was established in 2020 by Associate Professor Tania Vu and Dr. Thomas Jacob from OHSU Knight Cancer Institute and the Dept. of Biomedical Engineering . We are a seed stage company expediting the commercialization of a patented single cell functional precision medicine platform. Our goal is to empower the expanding universe of cancer targets and accelerate the clinical development of the most promising combination therapies to extend survival and escape disease relapse.
Our Team
Meet the Team
![](https://cytoimage.bio/wp-content/uploads/2022/01/dan.png)
Dan Snyder, MBA
CEO, Commercial Development
![](https://cytoimage.bio/wp-content/uploads/2022/01/tania.png)
Tania Vu, PhD
CSO, Co-founder
![](https://cytoimage.bio/wp-content/uploads/2022/01/sandra.png)
Sandra Shotwell, PhD
COO
![](https://cytoimage.bio/wp-content/uploads/2022/01/thomas.png)
Thomas Jacob, PhD
VP of R&D, Co-founder
![](https://cytoimage.bio/wp-content/uploads/2022/01/ann.png)
Ann Bunnenberg, PhD, JD
Board Chair, Co-founder
![](https://cytoimage.bio/wp-content/uploads/2022/03/Shula.jpg)
Shula Jaron, PhD
Director
People we trust
Partnerships and Collaborations
![](https://cytoimage.bio/wp-content/uploads/2022/01/cancer-institue.jpg)
![](https://cytoimage.bio/wp-content/uploads/2022/01/BD.png)
![](https://cytoimage.bio/wp-content/uploads/2022/01/ONAMI.png)
![](https://cytoimage.bio/wp-content/uploads/2022/03/20220303-NIH_NCI-logo.png)
Investors
![](https://cytoimage.bio/wp-content/uploads/2022/01/elevate-capital.png)
![](https://cytoimage.bio/wp-content/uploads/2022/01/wvc.png)
![](https://cytoimage.bio/wp-content/uploads/2022/01/ideaship.png)
![](https://cytoimage.bio/wp-content/uploads/2022/01/ONAMI.png)
![](https://cytoimage.bio/wp-content/uploads/2022/01/portland-seed-fund-1024x224.png)
Partner with Us.
The CytoImage leadership team is actively looking for investment and commercial partners to accelerate the development of single cell functional precision medicine.